Pharmaceutical composition for treating cognitive impairment and preparation method and applications thereof

Abstract

The invention belongs to the technical field of pharmacy, and in particular provides a pharmaceutical composition which is mainly composed of pseudo-ginseng and cape jasmine as crude medicines. The invention also provides a preparation method and applications of the pharmaceutical composition. Proved by experiments, the pharmaceutical composition provided by the invention has the efficacies of promoting blood circulation, removing obstruction in channels, detoxifying and promoting mentality, can effectively improve the cognitive function of patients with dementia or cognitive impairment, improves the abnormal behavior and life quality of patients, also can effectively target oxidative stress injury and micro-inflammation injury of brain cells, can increase energy supply for the brain cells, resists nerve cell apoptosis, promotes synaptic remodeling, has the effects of treating cognitive impairment, and is especially used for treating senile dementia or vascular dementia or minimal cognitive impairment or amnesia.

Description

A pharmaceutical composition for treating cognitive dysfunction and its preparation method and use technical field The invention relates to a pharmaceutical composition, which is mainly composed of raw materials notoginseng and gardenia, and has the effects of treating and relieving cognitive dysfunction or depression, especially treating and relieving senile dementia, vascular dementia, mildew The role of cognitive impairment or amnesia belongs to the technical field of traditional Chinese medicine. Background technique Cognitive dysfunction is a common core symptom of mild cognitive impairment (Mild Cognitive Impairment, MCI), dementia and amnesia, which seriously affects the life of patients. MCI is a transitional, pre-dementia pathological state between normal aging cognitive decline and very mild Alzheimer's disease (AD) and vascular dementia (VD). The earliest stage, first reported in 1990, was characterized by acquired cognitive impairment without significant impai...

AI Technical Summary

Problems solved by technology

However, there are still some deficiencies at present, mainly manifested in the fact that many clinical studies have not adopted unified standards for diagnosis, classification, and curative effect evaluation, and prescriptions, drug selection, and dosage vary from person to person, and cannot be standardized

At present, there is no literature report on the preparation of preparations only from the two raw materials of Panax notoginseng and Gardenia, especially the combination of these three drugs for the treatment of central nervous system degenerative diseases, and there is no relevant research

Images